Friday 6 November 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue: +14.5%
EPS: −43.6%
Free cash flow: +28.9%
Total debt: +142.7%

Quarter to September 2026, against a year earlier

110.32 3.28 −2.89%

Follow ABT

Alert me

Market cap: $196.6B
P/E: 42.3×
Fwd P/E: 35.1×
Dividend yield: 2.22%
F-score: 5/9
Altman Z: 5.61
Beneish M: −2.50
Dividend safety: 62/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Abbott Laboratories 10-Q filed Apr 30, 2025

Fiscal Q1 2025 · Period ended Mar 31, 2025 · Filed Apr 30, 2025 · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 31, 2024: no comparison — the earlier filing's text is no longer kept

Abbott Laboratories 10-Q filed Apr 30, 2025

What changed

Stockrow Weekly